SCHEMBL3346730

SCHEMBL3346730

O=C(N[C@H](Cc1ccccc1)c1ncc[nH]1)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.53
CTRB1 P17538 2/20 0.51
SSTR1 P30872 1/20 0.50
AAK1 Q2M2I8 3/20 0.48
CTSL P07711 4/20 0.47
CTSB P07858 3/20 0.47
CTSS P25774 3/20 0.47
CTSK P43235 1/20 0.46
ATM Q13315 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7451931 1.00 TACR1 (0.53) TACR1CTRB1SSTR1AAK1CTSL
SCHEMBL7417030 1.00 TACR1 (0.53) TACR1CTRB1SSTR1AAK1CTSL
SCHEMBL7421358 0.89 FPR2 (0.51) TACR1CTRB1SSTR1AAK1CTSL
SCHEMBL14923445 0.88 AAK1 (0.61) AAK1CTSLCTSBCTSSCTSK
SCHEMBL7466643 0.88 AAK1 (0.61) AAK1CTSLCTSBCTSSCTSK
SCHEMBL7466082 0.88 AAK1 (0.61) AAK1CTSLCTSBCTSSCTSK
SCHEMBL7418294 0.87 FPR2 (0.53) SSTR1AAK1CTSLCTSBCTSS
Trifluoroacetic Acid SCHEMBL8540672 0.85 AAK1 (0.55) AAK1CTSLCTSBCTSSCTSK
SCHEMBL391686 0.84 CYP1A2 (0.47) CYP3A4
SCHEMBL27724873 0.84 CYP1A2 (0.47) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 CN disclosed
WO-2012002577-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF 富士フイルム株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK TACR1 1502/4885CTRB1 2545/4885SSTR1 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.